Professor Yvonne Perrie

Professor Yvonne Perrie
Professor Yvonne Perrie
Yvonne Perrie's research team
Our research team

Professor in Pharmaceutics/Drug Delivery

Head of Pharmacy 

School of Life & Health Sciences
Aston University
Aston Triangle
Birmingham B4 7ET

email: y.perrie@aston.ac.uk
Telephone: +44 (0) 121 204 3991
Member of the Pharmacy and Biology Teaching Programmes

Research Theme

Chronic and Communicable Conditions

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA) 

Aston Research centre in CHildren and Young people's health(ARCHY)

Teaching Activity on the MPharm Programme

Pharmaceutics and drug delivery
Module co-ordinator for PH4701

Career History

2007 - date

Professor in Drug Delivery
Aston University

2005 - 07

Senior Lecturer in Pharmaceutics
Aston University

2000 - 05

Lecturer in Pharmaceutics
Aston University

1999 - 00

Pharmaceutical Scientist/Industrial Lecturer (joint position),
Lipoxen Ltd.
, The School of Pharmacy, University of London.

1998 - 99

Research Fellow, The School of Pharmacy,
University of London

1995 - 98

PhD, The School of Pharmacy, University of London
(Supervisor, Prof. G. Gregoriadis)

1994 - 95

Pre-registration Pharmacist training, R.W. McConnell & Son, Scotland.

1990 - 94

BSc Hons, Pharmacy (1st Class), University of Strathclyde

Research Interests

  • Formulation Engineering of Vaccines (including conventional and DNA vaccines)
  • Enhancing solubility and delivery of bioactive molecules using colloid science and technology.
  • Delivery of drugs, vaccines and gene therapies using liposomes, niosomes and other novel particulate systems
  • Design, physicochemical characterisation and development of non-viral systems for gene delivery
  • Tissue Engineering and regenerative medicine
  • Enhancing learning methods in Pharmacy Education

Membership of Professional Bodies

Research Support

My research group gratefully acknowledges the support of: EPSRC, EU 6th Framework programme, Lipoxen Technologies Ltd, Pfizer Global Research, Astisen Ltd, Wellcome, and The Royal Society.

Recent Publications 


  1. Nooshin Daneshpour, Russell Collighan*, Yvonne Perrie, Peter Lambert, Dan Rathbone, Deborah Lowry and Martin Griffin* (2012). Indwelling catheters and medical implants with FXIIIa inhibitors: a novel approach to the treatment of catheter and medical device-related infections, Eur J Pharm Biopharm. Accepted.
  2. Randip Kaur, Vincent Bramwell, Daniel J Kirby, Yvonne Perrie* (2012). Blocking the depot-formation of cationic liposomal adjuvants at the injection site, by reducing their size and pegylating their surface, promotes rapid antibody production but reduced Th1 responses. J Control Release. Accepted. 
  3. M.Habib Ali, Daniel J. Kirby, Afzal R Mohammed, Yvonne Perrie* (2012). The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs. International Journal of Pharmaceutics. Available online. http://dx.doi.org/10.1016/j.ijpharm.2012.06.056
  4. Sheraz Khan, Hannah Batchelor, Peter Hanson, Yvonne Perrie, and Afzal R Mohammed(2012). Dissolution rate enhancement, in vitro evaluation and investigation of drug release kinetics of chloramphenicol and sulphamethoxazole solid dispersions. Drug Development and Industrial Pharmacy. Accepted.
  5. Dennis Christensen, Malou Henriksen-Lacey, Arun T Kamath, Thomas Lindenstrøm, Karen S Korsholm, Jan P Christensen, Anne Rochat, Paul-Henri Lambert, Peter Andersen, Caire- Anne Siegrist, Yvonne Perrie and Else Marie Agger (2012). Vaccine adjuvants based on saturated quaternary ammonium lipids have different in vivo distribution kinetics and display distinct T cell-inducing capacity compared to their unsaturated analogues. J Control Release. J Control Release, 160 (3) 468-476.
  6. Anita Milicic, Randip Kaur, Arturo Reyes-Sandoval, Choon-Kit Tang, Jared Honeycutt, Yvonne Perrie and Adrian V S Hill (2012). Small cationic DDA:TDB liposomes as protein vaccine adjuvant obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS ONE. 7(3) e34255.
  7. Randip Kaur, Vincent Bramwell, Daniel J Kirby, Yvonne Perrie* (2012). Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses J Control Release. 158(3) 72-77.
  8. Yvonne Perrie*, Raj K Singh Badhan, Andrew Ingham, Daniel J Kirby, Deborah Lowry, Afzal R Mohammed and Defang Ouyang (2012). The impact of ageing on the barriers to drug delivery. J Control Release. 161(2) 389-398.
  9. Behfar Moghaddam, Sarah McNeil, Qinguo Zheng, Afzal R Mohammed and Yvonne Perrie* (2011). Exploring the correlation between lipid packaging in lipoplexes and their transfection efficacy. Pharmaceutics. 3(4), 848-864.
  10. Malou Henriksen-Lacey, Andrew Devitt and Yvonne Perrie* (2011). The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release. 154(2):131-7.
  11. Farhan Alhusban, Yvonne Perrie and Afzal UR Mohammed. (2011). Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. Eur J Pharm Biopharm. 2011 Nov;79(3):627-34.
  12. Sheraz Khan, Hannah Batchelor, Peter Hanson, Yvonne Perrie, and Afzal R Mohammed(2011). Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000. J Pharm Sci 100(10), 4281-4294. 

  13. Behfar Moghaddam, M Habib Ali, Jitinder Wilkhu, Daniel J Kirby, Afzal R Mohammed, Qinguo Zheng, and Yvonne Perrie* (2011).The application of monolayer studies in the understanding of liposomal formulations.Int J Pharm. 417 (1-2) 235-244. 

  14. R Jones, A Rajabi-siahboomi, M Levina, Y Perrie, A UR Mohammed (2011). The influence of formulation and manufacturing process parameters on the characteristics of lyophilised orally disintegrating tablets. Pharmaceutics. 3, 440-457.

  15. Jitinder Wilkhu, Sarah E McNeil, Daniel J Kirby and Yvonne Perrie* (2011). Formulation design considerations for oral vaccines. Therapeutic Delivery. 2(9) 1141-1164

  16. Myrra G. Carstens, Marcel G.M. Camps, Malou Henriksen-Lacy, Kees Franken, Tom H.M. Ottenhoff, Yvonne Perrie, Joke A. Bouwstra, Ferry Ossendorp, Wim Jiskoot (2011). Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29(29-30):4761-70.

  17. Malou Henriksen-Lacey, Karen Smith Korsholm, Yvonne Perrie, Peter Andersen, Dennis Christensen (2011). System Liposomal Vaccine Delivery systems. Expert opin Drug Deliv. 8(4):505-519.

  18. Randip Kaur,  Jili Chen, Amina Dawoodji, Vincenzo Cerundolo, Yoel R. Garcia-Diaz, Justyna Wojno, Liam R. Cox, Gurdyal S Besra, Behfar Moghaddam, Yvonne Perrie (2011). Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells. J Pharm Sci. 100(7):2724-33.

  19. Sarah McNeil, Helen R Griffiths and Yvonne Perrie (2011). Polycaprolactone fibres as a potential delivery system for collagen to support bone regeneration. Curr Drug Deliv.8(4)448-455.

  20. Sheraz Khan, Amr ElShaer , Ayesha S Rahman, Peter Hanson, Yvonne Perrie, and Afzal R Mohammed (2011). Systemic biology approach to study permeability of paracetamol and its solid dispersion. Int J Pharm. 417 (1-2) 272-279.

  21. Sagida Bibi, Randip Kaur, Malou Henriksen-Lacey, Sarah E. McNeil, Jitinder Wilkhu, Eric Lattmann, Dennis Christensen, Afzal R Mohammed and Yvonne Perrie* (2011). Microscope imaging of liposomes: From coverslips to environmental SEM. Int J Pharm. 417 (1-2) 138-150.

  22. Anjumn Shabir, Farhan AlHusban, Yvonne Perrie and Afzal R Mohammed (2011). Effects of ball-milling on PLGA polymer and its implication on lansoprazole-loaded nanoparticles. Journal of Basic and Clinical Pharmacy 2,71-82

  23. Sarah McNeil, Ida Rosenkrands, Else Marie Agger, Peter Andersen and Yvonne Perrie (2011). Subunit vaccines: Distearoylphosphatidylcholine based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium based cationic liposomes as an adjuvant delivery system. J Pharm Sci. 100(5)1856-65.

  24. Malou Henriksen-Lacey, Dennis Christensen, Vincent W. Bramwell, Thomas Lindenstrøm, Else-Marie Agger, Peter Andersen, Yvonne Perrie (2011). Comparison of the depot effect and immunogenicity of liposomes based on DDA, DC-Chol and DOTAP: Prolonged liposome retention mediates stronger Th1 responses. Molecular Pharmaceutics. Mol Pharm. 8(1):153-61.

  25. Khan S, Elshaer A, Rahman AS, Hanson P, Perrie Y, Mohammed AR (2011). Genomic evaluation during permeability of indomethacin and its solid dispersion. J Drug Target. 19 (8) 615-623.

  26. Nooshin Daneshpour, Martin Griffin, Russell Collighan and Yvonne Perrie. (2011) Targeted delivery of a novel group of site directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis. J Drug Target. 19 (8) 624-631.

  27. Ali, M.H., Kirby, DJ, Mohammed AR, Perrie Y (2010). Solubilisation of drugs within liposomal bilayers – alternatives to cholesterol as a membrane stabilising agent. J Pharm Pharmacol. 62 (11): 1646-1655.

  28. Afzal R Mohammed, Vincent W Bramwell, Daniel Kirby, Sarah E McNeil and Yvonne Perrie (2010). Increased Potential of a Cationic Liposome Based Delivery System: Enhancing Stability and Sustained Immunological Activity in Pre-Clinical Development. Eur J Pharm Biopharm. 2010 Nov;76(3):404-12.

  29. Deepa Mohanan, Malou Henriksen-Lacey, Bram Slütter, Wim Jiskoot, Joke Bouwstra , Yvonne Perrie, Thomas M. Kündig Bruno Gander, and PålJohansen (2010). Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 147(3), 342-249.

  30. Malou Henriksen-Lacey, Dennis Christensen, Vincent W. Bramwell, Thomas Lindenstrøm, Else-Marie Agger, Peter Andersen, Yvonne Perrie (2010). Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and immunogenicity of the vaccine. J Control Release. 145; 102-108.

  31. Malou Henriksen-Lacey, Vincent W. Bramwell and Yvonne Perrie (2010). Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics, 2, 91-104; doi:10.3390/pharmaceutics2020091.

  32. Farhan AlHusban, Yvonne Perrie and Afzal R Mohammed (2010). Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents.  Eur J Pharm Biopharm. 75(2), 254-262.

  33. McNeil SE, Vangala, A, Bramwell, VW, Hanson, PJ and Perrie, Y (2010). Lipoplexes formulation and optimisation: In vitro transfection studies reveal no correlation with in vivo vaccination studies. Current Drug Delivery. 7, 175-187.

  34. Chang, H-I., Wang, Y., Perrie, Y. and Coombes, A.G.A (2010). Microporous polycaprolactone matrices for drug delivery and tissue engineering: the release behavior of bioactive having extremes of aqueous solubility.  J Drug Del Sci Tech., 20(3) 207-212.

  35. Smith AM, Ingham A, Grover LM and Perrie Y (2010). Polymer film formulations for the preparation of enteric pharmaceutical capsules. J Pharm Pharmacol. 62 (2): 167-172.

  36. Malou Henriksen-Lacey, Vincent W. Bramwell, Dennis Christensen, Else-Marie Agger, Peter Andersen, Yvonne Perrie (2010). Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release. 142 (2) 180-186.

  37. Perrie Y, Ali H, Kirby DJ, Mohammed AU, McNeil SE, Vangala A (2010). Environmental scanning electron microscope imaging of vesicles. Methods Mol Biol; 606:319-331.

  38. Farahan Al Husban, Amr M. ElShaer, Jiteen H. Kansara, Alan M. Smith, Liam M. Grover, Yvonne Perrie and Afzal R. Mohammed (2010). Investigation of Formulation and Process of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid Combination. Pharmaceutics. 2(1), 1-17. http://www.mdpi.com/1999-4923/2/1/1/pdf

  39. Alhusban F, Perrie Y, Mohammed AR (2010). Preparation, Optimisation and Characterisation of Lyophilised Rapid Disintegrating Tablets Based on Gelatin and Saccharide. Curr Drug Deliv. 7, 65-75.

  40. R Kaur, R Morris, M Bencsik, A Vangala, T Rades, Y Perrie (2009) Development of a novel magnetic resonance imaging contrast agent for pressure measurements using lipid-coated microbubbles. J Biomed Nanotechnol. 5 (6), 1-9.

  41. Christensen D, Agger EM, Andreasen LV, Kirby, DJ, Andersen P, Perrie Y (2009). Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. J Liposome Res. 19(1) 2-11.

  42. Bhowruth V, Minnikin DE, Agger EM, Andersen P, Bramwell VW, Perrie Y*, Besra GS (2009) Adjuvant properties of a simplified C32 monomycolyl glycerol analogue. Bioorg Med Chem Lett. 2009 19(7) 2029-32.

  43. Hofmann, MP, Mohammed AR, Perrie Y, Gbureck U, Barralet JE* (2009) High Strength brushite bone cement with controlled drug releasing capabilities. Acta Biomater 5(1):43-49. (IF 3.1). 

  44. Perrie, Y*, Mohammed, A.R., Kirby, D.J., McNeil, S.E. and Bramwell, V.W. (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J Pharm. 364 272-280

  45. Clark, S., Cross, L M., Smith, A.M., Court, P., Vipond J, Nadian, A., Hewinson R.G., Batchelor H, K.,    Perrie, Y., Williams, A., Aldwell, F.E. &. Chambers, M.A. (2008) Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M Bovis. Vaccine. 26(46): 5791-7

  46. Perrie, Y*. (2008). Gregory Gregoriadis: Introducing liposomes to drug delivery. J Drug Target. 16(7):518-9.

  47. Kirby, DJ, Rosenkrands, I., Agger, E-M. Andersen, P., Coombes AGA., and Perrie, Y* (2008). Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J. Drug Target, 16(7):543-54.

  48. 17.  Robert H Morris, Martin Bencsik, Nikolaus Nestlé, Petrik Galvosas, David Fairhurst, Anil Vangala, Yvonne Perrie, Glen McHale (2008). Robust spatially resolved pressure measurements using MRI with novel buoyant-advection free preparations of stable microbubbles in polysaccharide gels. J Magn Reson; 193(2) :159-67.

  49. Christensen D, Kirby D, Foget C, Agger EM, Andersen P, Perrie Y, Nielsen HM (2008). alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying.Biochim Biophys Acta. 2008; 1778(5):1365-1373. 

  50. Kirby, DJ, Rosenkrands, I., Agger, E-M. Andersen, P., Coombes AGA., and Perrie, Y* (2008). PLGA microspheres for the delivery of a novel subunit TB vaccine J. Drug Target, 2008; 16(4) 282-293.

  51. Vangala, AK, R.H.Morris, RH, Bencsik, M, and Perrie, Y* (2007). Preparation and characterization of gas-filled liposomes: Can they improve oil recovery. J Liposome Res., 17(3):263-272.

  52. Smith, AM., Shelton, RM Perrie, Y and Harris, JJ* (2007). An initial evaluation of gellan gum as a material for tissue engineering applications. J Biomater Appl, 2007. 22(3); 241-254. doi:10.1177/0885328207076522

  53. *Perrie, Y., Mohammed, A.R., Vangala, A., and McNeil, S.E (2007). Environmental Scanning Electron Microscopy Studies of Liposomes and Niosomes, J Liposome Res. 17(1): 27-37.

  54.  *Perrie, Y., Kirby, DJ., Bramwell, V.W. and Mohammed, A.R (2007). Recent developments in particulate vaccines. Recent Patents on Drug Delivery & Formulation. 1, 117-129.

  55. R.H.Morris, RH*, Vangala, AK, Bencsik, M, Perrie, Y (2007) Three dimensional fluid pressure mapping in porous media using magnetic resonance imaging with gas filled liposomes. Mag. Res. Imaging, 2007, 25(4) 509-512. 

  56. Smith, AM., Harris, JJ, Shelton, RM and Perrie, Y*. (2007) 3D culture of bone-derived cells immobilized in alginate following light-triggered gelation. J. Control. Release.  94-101. 

  57. Vangala, A., Bramwell, V.W., McNeil, E, Christensen, D., Agger, E-M., and Perrie, Y*. (2007) Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control. Release. 119(1):102-110. 

  58. Mohammed, AR., Coombes, AGA., and *Perrie, Y (2007) Amino Acids as Cryoprotectants for Liposomal delivery systems. Euro J Pharm Sci, 406-413. 

  59. Mohammed, A.R., Bramwell, V.W., Coombes, A.G.A., *Perrie, Y (2006). Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods, 40: 30-38. 

  60. 29.  Vangala. A.K., Kirby, D., Rosenkrands, I., Agger, E-M., Andersen, P. and. *Perrie, Y (2006) A comparative study of cationic liposomes and niosome-based adjuvant systems for protein subunit vaccines: Characterisation, Environmental Scanning Electron Microscopy analysis and immunisation studies. J. Pharm Pharmacol, 58:787-799.

  61.  30.  Bramwell V.W. & Perrie, Y* (2006). Particulate delivery systems for vaccines: What can we expect? J. Pharm Pharmacol, 58:717-28.

  62. McNeil, S.E. and *Perrie, Y (2006). Gene Delivery using cationic lipids. Expert Opinion in Therapeutic Patents. 16(10):1371-1382.

  63. 32.  Chang, H-I., Perrie, Y. and *Coombes, A.G.A (2006). Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone.  J. Control. Release, 110:414-421

  64. Gorst, N.J.S.,  Perrie, Y., Gbureck, U.,  Hutton, A.L., Hofmann, M.P., Grover L.M.,  and Barralet J.E (2006). Effect of fibre reinforcement on the mechanical properties of brushite cement.  Acta Biomater, 2(1):95-102.

  65. Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E-M., *Andersen, P (2005). Characterization of cationic liposomes based on dimethyl dioctadecyl ammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6‘-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta, 1718, 22-31.

  66. Bramwell, V.W. & *Perrie, Y (2005) The rational design of vaccines. Drug Discov Today, 2005, 10 (22) 1527-1534.

  67.  Chang, H-I., Williamson, M.R., Perrie, Y. and *Coombes, A.G.A. Precipitation casting of Drug-loaded microporous PCL Matrices: Incorporation of Progesterone by co-dissolution.  J. Control. Release, 2005, 106,(3): 263-272. 37.  Bramwell, V.W. & *Perrie, Y (2005). Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst, 2005, 22(2):151-214.

  68. Bramwell, V.W. & *Perrie, Y (2005). Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst, 2005, 22(2):151-214

  69. Mohammed, A.R., Coombes, A.G.A, Fitzgerald, M., and *Perrie, Y (2004) Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability.Int. J. Pharm, 285, 23-34.

  70.  *Perrie, Y., Barralet, J.E., McNeil, S. and Vangala. A.K (2004) Liposome and niosome mediated DNA vaccination via the subcutaneous route. Int. J. Pharm, 284, 31-41.

  71.  *Perrie, Y., McNeil, S. and Vangala. A.K (2003). Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Targeting, 11, 555-563.

  72.  Perrie, Y. Obrenovic, M, McCarthy, D. and Gregoriadis, G (2002). Liposome-mediated DNA vaccination via the oral route. J Liposome Res, 12,185-197

  73.  Perrie, Y., Frederik P.M., and Gregoriadis, G (2001). Liposome-mediated immunisation: The effect of vesicle composition.Vaccine, 19, 3301-3310

  74.  Perrie, Y. and Gregoriadis, G (2000). Liposome-entrapped plasmid DNA: Characterisation Studies.  Biochim Biophys Acta, 1475,125-132.

  75. Gregoriadis, G., McCormack, B., Obrenovic, M., Saffie, R., Zadi, B. and Perrie, Y (1999). Vaccine entrapment in Liposomes. Methods, 19,156-162.


  76.   Rades T and Perrie Y (2011). Advanced characterisation techniques. International Journal of Pharmaceutics. 417 (1-2): 1-2.

  77. Perrie Y and Rades T (2010). Themed Issue. Improve dissolution, solubility and bioavailability of poorly soluble drugs. J Pharm Pharmacol. 62(11):1517-8

  78. Perrie Y. (2009). Liposomes, lipid assemblies, nanotechnology, and everything interesting in between. J liposome Res (Editorial). 19(1):1

  79. Perrie Y and Mohammed AR (2009). Pharmaceutics: A New Open-access journal for all those interested in designing medicines. 1(1), 1-2.  


  80. McNeil SE and Perrie Y (2010).  Developing a safe lypohilised adjuvant vaccine. Pharmaceutical Technology Europe. March 2010, p14.

  81. Perrie, Y*, Smith, AM., Harris, JJ, and Shelton, RM (2006). A new trick for an old delivery system. Pharm J.  277: 780.

  82. Perrie, Y. Influenza symptoms and treatments. Pharm J. 2006, 277: 399:402.

  83. Perrie, Y. Vaccines: an overview and update. Pharm J. 2006. 276(7388): 209-212.

  84. Perrie, Y (2005) How Pharmaceutical Scientists are going prospecting for black gold. Pharm J.  275(1): 809. 


  85. Perrie, Y. Optimisation of assessment and feedback in large-group practicals. J Pharm Pharmacol. 2004, 56.  

  86. Perrie, Y. Turning a dull lecture into an unforgettable learning experience. Pharm. J. 2003a, 270, 754-6.P  

  87. Perrie, Y. Virtual Learning Environments. Pharm. J. 2003b, 270, 794-5.  

  88.  Perrie, Y. Choosing an Assessment Strategy. Pharm. J. 2003c, 271, 86-88.   

  89. Wittingham, C and Perrie, Y. (2002). Application of “Exocharmic” Demonstrations in Pharmaceutics Lectures. Pharmacy Education, 2002, 2,157-8. 


  90.  Anderson D, Kirchmeier, M, Campbell, M, Wilkhu J, Perrie Y. Methods for preparing vesicles and formulations produced thereform. International PCT Patent Application No: PCT/US12/21389. Filed January 13.2011.   

  91. Mohammed AUR, Alhusban F, Perrie Y. Orally disintegrating tablets. UK Patent Application No 0920041.1.  

  92.  Smith, AM. & Perrie Y. Enteric Pharmaceutical Capsules. Filed 26/03/08 GB/29.3.07/GBA  0706178. PCT/GB2008001038  

  93. Perrie, Y. Griffiths, H.R., Phillips, D.C. Ceramide derivatives for the treatment of inflammation. 2004. Patent number W02004064823. (Published 05/08/2004)  

  94. Gregoriadis, G. and Perrie, Y. Liposome-entrapped DNA oral vaccines. 2001 Patent number WO0124773, (Published 12/04/2001)


  95. Bramwell, V.W. & Perrie, Y (2007). Natural and synthetic additives. European Biopharmaceutical Review. Spring: 78-83.  

  96. Perrie, Y (2005) Liposome delivery of sparingly soluble drugs.  European Biopharmaceutical Review. Autumn: 90-97.  

  97. Mohammed, A.R. & *Perrie, Y. (2005) Liposome solutions for sparingly soluble drugs. Drug Delivery Companies Report. Autumn/Winter, 2005, 9-11.


  98. Perrie Y (2012). Pharmaceutical nanotechnology and nanomedicines. In Aulton’s Pharmaceutics: The design and manufacture of medicines, 4th Edition, Churchill Livingston.   

  99. Bowman BJ, Ofner CM, Schott, H and Perrie Y (2012). Colloidal Dispersions. In Remington, The Science and Practice of Pharmacy. 22nd Edition. Lippincott Williams & Wilkins.

  100.   Perrie Y (2010). Vaccines for a new era. In The new optimists: scientists view tomorrow’s world & what it means to us. Linus Publishing.   

  101. Gregoriadis G, and Perrie Y. (2010). Liposomes. In Encyclopaedia of Life Sciences. John Wiley & Sons, UK. DOI: 10.1002/9780470015902.a0002656.pub2  

  102. ChristensenD, KorsholmK, WoodKJ, Mohammed AM, Bramwell VW, Agger EM and Perrie Y (2009). Liposomes as adjuvant systems for parenteral delivery of vaccines. In Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines.   

  103. Gregoriadis, G., McCormack, B., Perrie, Y., Bacon, A., Caparros-Wanderley, W. and Zadi, B.(2003). Liposome-based DNA vaccines: Procedures for entrapment. In Liposomes - A practical approach, 2nd ed., V.P. Torchilin, and V. Weissig eds. Oxford University Press. Practical Approach Series.   

  104. Perrie, Y. and Gregoriadis, G. (2000) Liposomal DNA Vaccines: Structural Characteristics. In Gregoriadis and McCormack, (Ed.) Targeting of Drugs, Targeting of Drugs: Strategies for Gene Constructs and Delivery. p. 102-111, Amsterdam, The Netherlands: IOS Press.  

  105. Gregoriadis, G., McCormack, B., Obrenovic, M., Perrie, Y. and Yang, J-C. (2000) Genetic Vaccines: A Role for Liposomes. In Gregoriadis and McCormack, (Ed.) Targeting of Drugs, Targeting of Drugs: Strategies for Gene Constructs and Delivery, p. 92-110. Amsterdam, The Netherlands: IOS Press.  

  106. Gregoriadis, G., McCormack, B., Obrenovic, M., Perrie, Y. and Saffie, R. (2000)
    Liposomes As Immunological Adjuvants and Vaccine Carriers. In O'Hagen D.T. (Ed). Methods in Molecular Medicine, vol 42, Vaccine Adjuvants: Preparation Methods and Research Protocols. p. 137-150. Totowa, NJ: Humana Press Inc

  107. Gregoriadis, G., McCormack, B., Obrenovic, M., and Perrie, Y. (1999) Entrapment of Plasmid DNA Vaccines into Liposomes by Dehydration/Rehydration. In Lowrie, D.B. and Whalen, R. (Eds.) Methods in Molecular Medicine, vol 9, DNA Vaccines: Methods and Protocols. p. 305-312. Totowa, NJ: Humana Press Inc.  

  108. Gregoriadis, G., McCormack, B., Morrison (Perrie), Y., Saffie, R. and Zadi, B. (1998) Liposomes in drug targeting. In: Cellis, J.E. (Ed.) Cell biology: A laboratory handbook, 2nd edn. p. 131-140. New York: Academic Press.  

  109.  Gregoriadis, G., McCormack, B., Perrie, Y. and Saffie, R. (1998) DNA Vaccination: A role for liposomes. In: Lasic, D.D. and Papahadjopoulos, D. (Eds.) Medical applications of liposomes, p. 61-73. New York: Elsevier Science  

  110. Gregoriadis, G., McCormack, B., Perrie, Y. and Saffie, R. (1998) Liposome-mediated DNA vaccination. In: Janoff, A. (Ed.) Liposomes: Rational Design, p. 205-218. New York: Marcel Dekker, Inc 

YP 1

111. FASTtrack Pharmaceutics – Drug Delivery and Targeting (2009). Yvonne Perrie
nd Thomas Rades. London: Pharmaceutical Press. 

112. FASTtrack Pharmaceutics – Drug Delivery and Targeting (2012). Yvonne Perrie and       Thomas Rades. London: Pharmaceutical Press. Second Edition.   

113. Remington: The Science and Practice of Pharmacy (2012). 22nd Edition
harmaceutical Press. Editor-in-chief Loyd Allen, Jr

YP pic 2

114. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines (2012). Darren Flower and Yvonne Perrie. Springer. In

Currently Yvonne and her group have published numerous abstracts with students currently averaging around 3 to 4 per year (see Appendix I).

Employable Graduates; Exploitable Research